08/10/2003
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’), a company developing a potential treatment for Alzheimer’s disease, announces that a manuscript reviewing the full results of its clinical study RG-010 has been accepted in its final form for publication in the Journal of Alzheimer’s Disease (the ‘Journal’). The publishers of the Journal advise that the article will appear in their February 2004 edition.
Clinical study RG-010 compared Colostrinin™ with a placebo in the treatment of 106 patients with mild or moderate Alzheimer’s disease. Headline results at completion of the 30-week study were as follows:
• Approximately 40% of patients on Colostrinin™ were stabilised or improved after 15 weeks of therapy, based on an Analysis of Overall Response
• 33% of patients continued to show stabilisation or improvement after 30 weeks of treatment, although levels of benefit were slightly higher at the 15-week stage of the trial
• Efficacy demonstrated in both mild and moderate symptom groups, with greatest effects seen in earlier stages of the disease
• No drug-related Serious Adverse Events or safety concerns were observed during the trial
Percy Lomax, ReGen’s Executive Chairman commented ‘We are pleased that the full results of the study will be published in this international peer reviewed journal that focuses on all aspects of the management of Alzheimer’s disease. We believe that the publication of the article will communicate the potential of Colostrinin™ as a safe and effective therapy for Alzheimer’s disease to a much wider audience, including potential development and/or marketing partners’.
Further information:
Andrew Marshall
Marshall Robinson Roe
Tel No: 020 7960 6007